234 related articles for article (PubMed ID: 35967339)
1. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells
Focaccetti C; Benvenuto M; Pighi C; Vitelli A; Napolitano F; Cotugno N; Fruci D; Palma P; Rossi P; Bei R; Cifaldi L
Front Immunol; 2022; 13():886319. PubMed ID: 35967339
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
Veneziani I; Infante P; Ferretti E; Melaiu O; Battistelli C; Lucarini V; Compagnone M; Nicoletti C; Castellano A; Petrini S; Ognibene M; Pezzolo A; Di Marcotullio L; Bei R; Moretta L; Pistoia V; Fruci D; Barnaba V; Locatelli F; Cifaldi L
Cancer Immunol Res; 2021 Feb; 9(2):170-183. PubMed ID: 33303573
[TBL] [Abstract][Full Text] [Related]
3. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
4. DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.
Cifaldi L; Melaiu O; Giovannoni R; Benvenuto M; Focaccetti C; Nardozi D; Barillari G; Bei R
Front Immunol; 2023; 14():1197053. PubMed ID: 37359555
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
6. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
Cho MM; Song L; Quamine AE; Szewc F; Shi L; Erbe AK; Ebben JD; Turicek DP; Kline JM; Lafeber EO; Phillips MF; Ceas AS; Capitini CM
bioRxiv; 2024 Jan; ():. PubMed ID: 37333207
[TBL] [Abstract][Full Text] [Related]
7. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
[TBL] [Abstract][Full Text] [Related]
8. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
[TBL] [Abstract][Full Text] [Related]
9. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
10. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
[TBL] [Abstract][Full Text] [Related]
12. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.
Pende D; Bottino C; Castriconi R; Cantoni C; Marcenaro S; Rivera P; Spaggiari GM; Dondero A; Carnemolla B; Reymond N; Mingari MC; Lopez M; Moretta L; Moretta A
Mol Immunol; 2005 Feb; 42(4):463-9. PubMed ID: 15607800
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
Labani-Motlagh A; Israelsson P; Ottander U; Lundin E; Nagaev I; Nagaeva O; Dehlin E; Baranov V; Mincheva-Nilsson L
Tumour Biol; 2016 Apr; 37(4):5455-66. PubMed ID: 26563374
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
[TBL] [Abstract][Full Text] [Related]
16. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
18. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
19. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
20. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E; Veneziani I; Melaiu O; Pezzolo A; Castellano A; Boldrini R; Ferretti E; Fruci D; Moretta L; Pistoia V; Locatelli F; Cifaldi L
Oncoimmunology; 2017; 6(6):e1316439. PubMed ID: 28680748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
